379 related articles for article (PubMed ID: 20083161)
1. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
2. Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Freitas BC; Cerutti JM
Mol Cell Endocrinol; 2010 May; 321(1):77-85. PubMed ID: 19932149
[TBL] [Abstract][Full Text] [Related]
3. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
4. [Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations].
Hayashi N; Kitaoka M
Nihon Rinsho; 2007 Nov; 65(11):2003-7. PubMed ID: 18018562
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma.
Guerra LN; Miler EA; Moiguer S; Karner M; Orlandi AM; Fideleff H; Burdman JA
Clin Chim Acta; 2006 Aug; 370(1-2):180-4. PubMed ID: 16600201
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
7. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
8. Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
Letsas KP; Vartholomatos G; Tsepi C; Tsatsoulis A; Frangou-Lazaridis M
Neoplasma; 2007; 54(1):57-62. PubMed ID: 17203893
[TBL] [Abstract][Full Text] [Related]
9. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy.
Williams MD; Suliburk JW; Staerkel GA; Busaidy NL; Clayman GL; Evans DB; Perrier ND
Ann Surg Oncol; 2009 Nov; 16(11):3146-53. PubMed ID: 19727961
[TBL] [Abstract][Full Text] [Related]
11. Circulating thyroid cancer markers.
Gupta M; Chia SY
Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):383-8. PubMed ID: 17940468
[TBL] [Abstract][Full Text] [Related]
12. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
Lupo M; Guttler R; Geck Z; Tonozzi TR; Kammesheidt A; Braunstein GD
Endocr Pract; 2018 May; 24(5):453-459. PubMed ID: 29498908
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in the clinical application of thyroid cancer biomarkers.
Shibru D; Chung KW; Kebebew E
Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
[TBL] [Abstract][Full Text] [Related]
14. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
15. ADM3, TFF3 and LGALS3 are discriminative molecular markers in fine-needle aspiration biopsies of benign and malignant thyroid tumours.
Karger S; Krause K; Gutknecht M; Schierle K; Graf D; Steinert F; Dralle H; Führer D
Br J Cancer; 2012 Jan; 106(3):562-8. PubMed ID: 22223087
[TBL] [Abstract][Full Text] [Related]
16. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.
Cantara S; Capezzone M; Marchisotta S; Capuano S; Busonero G; Toti P; Di Santo A; Caruso G; Carli AF; Brilli L; Montanaro A; Pacini F
J Clin Endocrinol Metab; 2010 Mar; 95(3):1365-9. PubMed ID: 20130073
[TBL] [Abstract][Full Text] [Related]
17. Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy.
Mazeh H; Levy Y; Mizrahi I; Appelbaum L; Ilyayev N; Halle D; Freund HR; Nissan A
J Surg Res; 2013 Apr; 180(2):216-21. PubMed ID: 22626557
[TBL] [Abstract][Full Text] [Related]
18. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
19. [Use of BRAF V600E mutation in the differential diagnosis of follicular and papillary tumors of the thyroid and for the optimization of thearpy].
Semënov DIu; Boriskova ME; Zaraĭskiĭ MI; Saburova IIu; Pankova PA; Farafonova UV; Bykov MA
Vopr Onkol; 2012; 58(5):649-52. PubMed ID: 23600282
[TBL] [Abstract][Full Text] [Related]
20. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.
Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK
Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
